HomeCompareAKRFF vs PFE

AKRFF vs PFE: Dividend Comparison 2026

AKRFF yields 2063.98% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKRFF wins by $13331039307.17M in total portfolio value
10 years
AKRFF
AKRFF
● Live price
2063.98%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13331039307.22M
Annual income
$12,171,036,297,947,368.00
Full AKRFF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AKRFF vs PFE

📍 AKRFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKRFFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKRFF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKRFF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKRFF
Annual income on $10K today (after 15% tax)
$175,438.60/yr
After 10yr DRIP, annual income (after tax)
$10,345,380,853,255,262.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AKRFF beats the other by $10,345,380,853,232,942.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKRFF + PFE for your $10,000?

AKRFF: 50%PFE: 50%
100% PFE50/50100% AKRFF
Portfolio after 10yr
$6665519653.63M
Annual income
$6,085,518,148,986,813.00/yr
Blended yield
91.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AKRFF
No analyst data
Altman Z
-0.2
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKRFF buys
0
PFE buys
0
No recent congressional trades found for AKRFF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKRFFPFE
Forward yield2063.98%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$13331039307.22M$49.6K
Annual income after 10y$12,171,036,297,947,368.00$26,258.71
Total dividends collected$13248903950.40M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AKRFF vs PFE ($10,000, DRIP)

YearAKRFF PortfolioAKRFF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$217,098$206,398.35$9,153$693.39+$207.9KAKRFF
2$4,420,028$4,187,732.78$8,593$849.25+$4.41MAKRFF
3$84,412,065$79,682,634.57$8,336$1,066.78+$84.40MAKRFF
4$1,512,516,762$1,422,195,852.90$8,437$1,384.80+$1512.51MAKRFF
5$25,434,529,072$23,816,136,137.07$9,013$1,875.40+$25434.52MAKRFF
6$401,507,365,308$374,292,419,200.69$10,306$2,680.72+$401507.36MAKRFF
7$5,951,621,357,208$5,522,008,476,328.59$12,820$4,101.38+$5951621.34MAKRFF
8$82,867,113,366,068$76,498,878,513,854.90$17,673$6,826.70+$82867113.35MAKRFF
9$1,084,114,961,932,747$995,447,150,631,054.80$27,543$12,591.86+$1084114961.91MAKRFF
10$13,331,039,307,215,410$12,171,036,297,947,368.00$49,560$26,258.71+$13331039307.17MAKRFF

AKRFF vs PFE: Complete Analysis 2026

AKRFFStock

Ackroo Inc. develops and sells an online loyalty and rewards platform that enables businesses to design and execute customer transaction, engagement, and retention strategies primarily in North America. It enables small to medium sized businesses to automate the processing and management of gift card and loyalty transactions to increase profitability and build long-term customer relationships. The company's cloud-based marketing platform provides merchants an in-store and online process to manage loyalty, gift card, and promotional transactions at the point of sale; a program to help them view data for reconciliation, reporting, and marketing; and customer interfaces to allow merchant's consumers to register, check, transfer, and reload balances. It also provides AckrooPOS/GGGolf platform for golf clubs, which integrates accounting and hospitality point of sale options and other services; and offers handicapping services, as well as to manage tee-sheets, lottery, and tournaments. In addition, the company offers marketing services, including email and direct mail marketing, and design services; and payment services comprising credit and debit card processing services. It serves automotive, petroleum, hospitality, and retail markets. Ackroo Inc. was founded in 2012 and is headquartered in Hamilton, Canada.

Full AKRFF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AKRFF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKRFF vs SCHDAKRFF vs JEPIAKRFF vs OAKRFF vs KOAKRFF vs MAINAKRFF vs JNJAKRFF vs MRKAKRFF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.